Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5845765 | Pulmonary Pharmacology & Therapeutics | 2013 | 5 Pages |
Abstract
PRM-151 administration was generally well tolerated. In two pulmonary fibrosis patients non-specific, transient skin reactions (urticaria and erythema) were observed. PRM-151 administration resulted in a 6-to 13-fold increase in mean baseline plasma SAP levels at dose levels of 5, 10, and 20Â mg/kg. The estimated t1/2 of PRM-151 in healthy volunteers was 30Â h. Pharmacokinetic profiles were comparable between healthy volunteers and PF patients. PRM-151 administration resulted in a 30-50% decrease in fibrocyte numbers 24Â h post-dose. This suggests that administration of PRM-151 may be associated with a reduction of fibrocytes in PF patients, a population for which current pharmacotherapeutic options are limited. The pharmacological action of PRM-151 should be confirmed in future research.
Keywords
TGF-βIIPPDGFFACSLPSMCP-1IL-1PBMCIPFEnzyme linked immunoassayinterleukin-1transforming growth factor-βELISAtumor necrosis factor-αSerum Amyloid PPeripheral blood mononuclear cellFIHSAPAdverse eventsPharmacodynamicsPharmacokineticsplatelet derived growth factorTNF-αfluorescence activated cell sorterPulmonary fibrosisidiopathic pulmonary fibrosisFibrocytelipopolysaccharideMacrophagemonocyte chemoattractant protein-1Idiopathic interstitial pneumonia
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
M.R. Dillingh, B. van den Blink, M. Moerland, M.G.J. van Dongen, M. Levi, A. Kleinjan, M.S. Wijsenbeek, M.L. Jr., D.M. Harper, J.A. Getsy, H.C. Hoogsteden, J. Burggraaf,